MicroRNA-608 and microRNA-34a regulate chordoma malignancy by targeting EGFR, Bcl-xL and MET

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Chordomas are rare malignant tumors arising from notochord remnants, lacking effective adjuvant and molecular therapies beyond surgery and radiation.
• The molecular pathogenesis of chordoma remains poorly understood, highlighting a critical need for novel therapeutic targets.
• MicroRNAs (miRNAs) are key regulators in cancer, but their specific roles in chordoma are largely unexplored.

Purpose of the Study:

• To investigate the role of microRNAs in chordoma malignancy.
• To identify novel tumor suppressive miRNAs and their molecular targets in chordoma.
• To explore the therapeutic potential of restoring miRNA expression in chordoma.

Main Methods:

• Expression analysis of miR-608 and miR-34a in human chordoma cell lines and primary cells.
• Identification of direct oncogene targets (EGFR, Bcl-xL, MET) using bioinformatics and experimental validation.
• Functional studies involving restoration of miRNA expression and pharmacological inhibition of target oncogenes.

Main Results:

• miR-608 and miR-34a expression is downregulated in chordoma, partly due to copy number alterations.
• EGFR, Bcl-xL, and MET were identified as direct targets of miR-608 and miR-34a.
• Restoration of miR-608 and miR-34a inhibited chordoma cell proliferation, invasion, and induced apoptosis, while target inhibition showed similar effects.

Conclusions:

• miR-608 and miR-34a function as tumor suppressors in chordoma.
• These miRNAs regulate chordoma malignancy by targeting oncogenes EGFR, MET, and Bcl-xL.
• Restoring miR-608 and miR-34a represents a promising therapeutic strategy for chordoma.